Australia has two biosimilar insulins, and P2 Chat is here to help you get your head around what this means for people with diabetes. Jayne Lehmann and Kirrily Chambers chat out about insulin production, the difference between a generic, biosimilar and bio-equivalent medication, and insulin pricing around the world. (NB This Chat was recorded at the end of 2019, and with the launch of the second biosimilar in Australia, Optisulin an addendum chat has been added on to the original chat.) First published 29/4/2020